Citius Pharmaceuticals Shares Surge 22% After Launch of LYMPHIR Therapy

Citius Pharmaceuticals Inc. (NASDAQ:CTXR) experienced a significant surge of 22.12% in after-hours trading on Tuesday, closing at $1.27. This increase follows the company’s fiscal year 2025 business update and the commercial launch of its leading oncology therapy, LYMPHIR.

Launch of LYMPHIR Marks a Milestone in Oncology Treatment

The New Jersey-based biopharmaceutical firm announced that LYMPHIR (denileukin diftitox-cxdl), a recombinant engineered fusion protein, became commercially available in December 2023 through its subsidiary, Citius Oncology (NASDAQ:CTOR). Approved by the U.S. Food and Drug Administration, LYMPHIR is indicated for adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL) who have undergone at least one prior systemic therapy. Leonard Mazur, Chairman and CEO of Citius Pharmaceuticals, stated in the company’s press release, “This milestone reflects our ability to execute and our commitment to delivering impactful treatments for patients with limited options.”

Citius Pharmaceuticals has made strides in market access by obtaining a permanent Healthcare Common Procedure Coding System J-code (J9161) and a recommendation from the National Comprehensive Cancer Network as a Category 2A treatment. The company has established service agreements with three leading U.S. pharmaceutical wholesalers, ensuring nationwide availability of LYMPHIR, with an estimated 18 months of commercial supply already secured. Additionally, the therapy is accessible in 19 international markets through named patient programs, further expanding its reach.

Financial Overview and Future Outlook

In its fiscal year 2025 report, Citius Pharmaceuticals recorded a net loss of $39.7 million, which equates to $3.38 per share. This reflects a slight improvement from a net loss of $40.2 million, or $5.97 per share, in fiscal year 2024. The company raised approximately $61 million in gross proceeds through various capital raises but reported having only $4.3 million in cash and cash equivalents as of September 30, 2023. Research and development expenses decreased to $9.2 million from $11.9 million year over year, while general and administrative expenses rose slightly to $18.5 million from $18.2 million. Notably, Citius Pharmaceuticals reported no revenue for the fiscal year.

Trading metrics indicate that Citius Pharmaceuticals has a Relative Strength Index (RSI) of 42.25 and a market capitalization of $16.57 million. The stock has reached a 52-week high of $5.95 and a 52-week low of $0.65. Over the past year, shares of CTXR have declined by 66.77%, highlighting ongoing challenges faced by the company and the need for cautious trading strategies.

On Tuesday, CTXR closed at $1.04, a decrease of 0.95%. The stock is currently about 7.4% above its 52-week low, suggesting it remains closer to its lows than its highs, which may indicate potential volatility moving forward. As Citius Pharmaceuticals continues to navigate its commercial landscape, the successful launch of LYMPHIR may pave the way for future growth and opportunities in the oncology sector.